Andrew Lake, MD
Gastroenterology · Gainesville, GANPI 1821224809
Payments from drug & device makers
Across 502 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$999
- Johnson & Johnson$687
- Takeda Pharmaceuticals U.S.A., Inc.$519
- Gilead$503
- Intercept Pharmaceuticals, Inc.$440
- plus $4K from 35 others
What the payments were for
- Food & beverage$8,45698%
- Education$2132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,669 in reported general payments places this provider in the 70th percentile of 492 gastroenterology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 14 | $65,713 |
| XifaxanRifaximin | 17 | $47,859 |
| LinzessLinaclotide | 61 | $41,792 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 77 | $12,295 |
| MotegrityPrucalopride Succinate | 13 | $6,769 |
| Sucralfate | 119 | $4,335 |
| Omeprazole | 362 | $3,920 |
| Mesalamine ErMesalamine | 14 | $3,787 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 16 | $2,705 |
| Budesonide DrBudesonide | 26 | $2,484 |
| Mesalamine | 18 | $2,436 |
| Lubiprostone | 13 | $2,329 |
| Colesevelam Hcl | 12 | $2,321 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 34 | $2,225 |
| Budesonide EcBudesonide | 11 | $2,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $32 | $65,71314 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $999 | $47,85917 claims |
| AbbVieLinzess | $1,920 | $41,79261 claims |
| Braintree Laboratories, Inc.Sutab | $17 | $12,29577 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $519 | $6,76913 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $97 | $2,70516 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 492 gastroenterology providers in Georgia.
Other gastroenterology in Gainesville
- Scott ClarkGainesville$86K
- Jawad IlyasGainesville$40K
- Douglas WolfAtlanta$6.4M
- Aasim SheikhMarietta$6M
- Shahriar SedghiMacon$5.4M
- Jeffrey WilliamsAthens$2.5M
- Michael GalambosAtlanta$1.8M
- Nitin GuptaAtlanta$1.7M
- Bruce SalzbergSuwanee$1.4M
- Heba IskandarAtlanta$978K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.